Personalis Operating Income 2018-2024 | PSNL

Personalis operating income from 2018 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Personalis Annual Operating Income
(Millions of US $)
2023 $-110
2022 $-116
2021 $-65
2020 $-42
2019 $-22
2018 $-14
2017 $-22
Personalis Quarterly Operating Income
(Millions of US $)
2024-06-30 $-17
2024-03-31 $-19
2023-12-31 $-24
2023-09-30 $-31
2023-06-30 $-25
2023-03-31 $-30
2022-12-31 $-32
2022-09-30 $-27
2022-06-30 $-28
2022-03-31 $-28
2021-12-31 $-20
2021-09-30 $-18
2021-06-30 $-15
2021-03-31 $-12
2020-12-31 $-13
2020-09-30 $-10
2020-06-30 $-9
2020-03-31 $-10
2019-12-31 $-7
2019-09-30 $-6
2019-06-30 $-4
2019-03-31 $-5
2018-12-31
2018-09-30 $-2
2018-06-30 $-4
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.270B $0.073B
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
BridgeBio Pharma (BBIO) United States $4.791B 0.00
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00